Unlabelled: The aim of this study was to evaluate the prevalence of Helicobacter Pylori (HP) infection in a representative group of workers in Timiş County.
Material And Methods: Our study population consisted of 960 employees: 206 F (21.46%) and 754 M (78.54%), mean age 36.8+/-7.6 years (range 18-60 years) from a company in Timişoara, in whom we assessed IgG anti HP antibodies. We standardised our study population for the age and gender distribution of the population in Timiş County and we excluded under 18 and over 60 years age groups which were underrepresented.
Results: Antibodies were found in 691 individuals (71.9%). In females, the prevalence of HP infection was 63.1% (130/206) and in males 74.4% (561/754). In the age group 18-30 years - 65.3%, males-67%, females-56.8% (p=0.240); in group 31 - 40 years - 71.6%, males-74.4%, females-63.5% (p=0.025); in group 41 - 50 years - 75%, males - 78%, females-62.5% (p=0.026); and in group 51 - 60 years - 88.7 %, males-87.2 %, females - 100% (p=0.35). After standardisation for age and gender, the prevalence of HP infection in the adult population was 68.5%; in females - 63.8 %, in males - 73.5% (p=0.08).
Conclusions: In a population sample significant for Timiş County, the prevalence of HP infection is 68.5% in the adult population, slightly higher in males than in females (74.4% vs 63.1) (p=0.08), and it has a tendency to increase with ag
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Approach to Scabies in Children: An Update].
Acta Med Port
January 2025
Serviço de Dermatologia. Unidade Local de Saúde Santo António. Porto. Portugal.
Scabies is a common dermatological infection that globally affects more than 200 million people. It is caused by the parasite Sarcoptes scabiei var. hominis and its transmission primarily occurs through direct contact.
View Article and Find Full Text PDFPopulation-level Impact of HPV Vaccination on the Incidence of Genital Warts in Sweden.
J Infect Dis
January 2025
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels väg 12A, SE-17177 Stockholm, Sweden.
Background: Sweden introduced HPV vaccination in 2006, administered through opportunistic, subsidized, catch-up and school-based programs. Notably, genital warts (GW) are the first observable clinical outcome following infection by HPV-6/11, targeted by vaccination. We aim to gain knowledge of the incidence of GW in Sweden and evaluate its change throughout vaccination programs.
View Article and Find Full Text PDFScaling Up Kangaroo Mother Care Through a Facility Delivery Model in Rural Districts of Pakistan: Protocol for a Mixed Methods Study.
JMIR Res Protoc
January 2025
Centre of Excellence in Women and Child Health, Aga Khan University, Karachi, Pakistan.
Background: The neonatal mortality rate in Pakistan is the third highest in Asia, with 8.6 million preterm babies. These newborns require warmth, nutrition, and infection protection, typically provided by incubators.
View Article and Find Full Text PDFOral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.
N Engl J Med
January 2025
From Médecins Sans Frontières (L.G., F.V.), Sorbonne Université, INSERM Unité 1135, Centre d'Immunologie et des Maladies Infectieuses (L.G.), Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Universitaire Sorbonne Université, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux (L.G.), and Epicentre (M.G., E. Baudin), Paris, and Translational Research on HIV and Endemic and Emerging Infectious Diseases, Montpellier Université de Montpellier, Montpellier, Institut de Recherche pour le Développement, Montpellier, INSERM, Montpellier (M.B.) - all in France; Interactive Development and Research, Singapore (U.K.); McGill University, Epidemiology, Biostatistics, and Occupational Health, Montreal (U.K.); UCSF Center for Tuberculosis (G.E.V., P.N., P.P.J.P.) and the Division of HIV, Infectious Diseases, and Global Medicine (G.E.V.), University of California at San Francisco, San Francisco; the National Scientific Center of Phthisiopulmonology (A.A., E. Berikova) and the Center of Phthisiopulmonology of Almaty Health Department (A.K.), Almaty, and the City Center of Phthisiopulmonology, Astana (Z.D.) - all in Kazakhstan; Médecins Sans Frontières (C.B., I.M.), the Medical Research Council Clinical Trials Unit at University College London (I.M.), and St. George's University of London Institute for Infection and Immunity (S.W.) - all in London; MedStar Health Research Institute, Washington, DC (M.C.); Médecins Sans Frontières, Mumbai (V. Chavan), the Indian Council of Medical Research Headquarters-New Delhi, New Delhi (S. Panda), and the Indian Council of Medical Research-National AIDS Research Institute, Pune (S. Patil) - all in India; the Centre for Infectious Disease Epidemiology and Research (V. Cox) and the Department of Medicine (H. McIlleron), University of Cape Town, and the Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine (S.W.) - both in Cape Town, South Africa; the Institute of Tropical Medicine, Antwerp, Belgium (B. C. J.); Médecins Sans Frontières, Geneva (G.F., N.L.); Médecins Sans Frontières, Yerevan, Armenia (O.K.); the National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia (N.K.); Partners In Health (M.K.) and Jhpiego Lesotho (L.O.) - both in Maseru; Socios En Salud Sucursal Peru (L.L., S.M.-T., J.R., E.S.-G., D.E.V.-V.), Hospital Nacional Sergio E. Bernales, Centro de Investigacion en Enfermedades Neumologicas (E.S.-G.), Hospital Nacional Dos de Mayo (E.T.), Universidad Nacional Mayor de San Marcos (E.T.), and Hospital Nacional Hipólito Unanue (D.E.V.-V.) - all in Lima; Global Health and Social Medicine, Harvard Medical School (L.L., K.J.S., M.L.R., C.D.M.), Partners In Health (L.L., K.J.S., M.L.R., C.D.M.), the Division of Global Health Equity, Brigham and Women's Hospital (K.J.S., M.L.R., C.D.M.), the Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, (L.T.), and Harvard T.H. Chan School of Public Health (L.T.) - all in Boston; and the Indus Hospital and Health Network, Karachi, Pakistan (H. Mushtaque, N.S.).
Background: For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs to treat tuberculosis and enhanced funding now permit randomized, controlled trials of shortened-duration, all-oral treatments for rifampin-resistant tuberculosis.
Methods: We conducted a phase 3, multinational, open-label, randomized, controlled noninferiority trial to compare standard therapy for treatment of fluoroquinolone-susceptible, rifampin-resistant tuberculosis with five 9-month oral regimens that included various combinations of bedaquiline (B), delamanid (D), linezolid (L), levofloxacin (Lfx) or moxifloxacin (M), clofazimine (C), and pyrazinamide (Z).
Estimating the economic consequences of leveraging the novel cobas® HIV-1/HIV-2 Qualitative NAT Test in routine HIV testing.
Clin Infect Dis
January 2025
IQVIA Inc., Falls Church, VA.
Article Synopsis
- The study compared the costs of the current CDC 3-step HIV testing algorithm with a new single-test alternative (cobas) for efficiency in diagnosing HIV.
- A decision-tree model estimated costs and testing needs for 1 million people, revealing significant reductions in total tests and retests required when using the alternative method.
- Findings indicate that the new algorithm could simplify HIV testing processes, cut overall testing numbers, and keep healthcare costs stable, thereby improving patient outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!